Liron Leibovitch - research works

A total of 5,632 eligible articles were identified.

This article provides relevant information from 12 studies involving 6,849 patients, of which 3,414 were female.

The earliest publication date was September 16, 2021, while the latest was June 11, 2024.

High heterogenicity was found for fatigue, brain fog, and anxiety due to the diverse methodologies employed in the studies.

Out of a total of 1,738 studies initially considered, only 20 met the criteria for inclusion.

Most studies showed a greater number of female patients.

In Tokyo, sarcoidosis accounts for 8.9% of uveitis cases, making it the most systemic association cause.

The results indicated significant differences in gut microbiota between migraine patients and controls.

Conversely, Veillonella exhibited elevated abundance compared to controls.

However, the optimal surgical approach remains uncertain.

The primary outcome was the incidence of allogeneic blood transfusions, while secondary outcomes included blood loss and surgical complications, such as dislocations, periprosthetic fractures, and infections.

No significant difference was observed in the number of allogeneic blood transfusions between the two approaches (RR = 1.04; 95% CI: 0.76 to 1.43; p=0.63).

However, there was no significant difference in the rates of surgical complications between the two groups (RR = 0.63; 95% CI: 0.32 to 1.26; p=0.12).

To date, several potential interventions for brain fog have been considered.

We included studies on adult (aged > 18 years) individuals with proven long- COVID brain-fog symptoms from PubMed, MEDLINE, Central, Scopus, and Embase.

A search limit was set for articles published between 01/2020 and 31/12/2023.

We excluded studies lacking an objective assessment of brain fog symptoms and patients with preexisting neurological diseases that affected cognition before COVID-19 infection.